

<b>Hemonor</b> Micronized Diosmin INN 450 mg + Hesperidin INN 50 mg	<b>Tablet</b>
---	---------------

**COMPOSITION**

Each film coated tablet contains micronized Diosmin INN 450 mg and Hesperidin INN 50 mg.

**PHARMACOLOGY**

**Hemonor** is a phlebotonic drug and a vascular protecting agent. It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus it decreases venous capacitance, venous distensibility and venous emptying time. **Hemonor** protects the microcirculation by fighting the microcirculation damaging process; It combats venous inflammation by decreasing leukocyte activation and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandin. Thus **Hemonor** normalizes capillary permeability and strengthens capillary resistance. **Hemonor** acts on the lymphatic system. It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure.

**INDICATION**

- Acute hemorrhoidal attacks.
- Chronic hemorrhoidal disease.
- Organic and functional chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs, pain, nocturnal cramps.

**DOSAGE AND ADMINISTRATION**

Tablet should be taken at meal times.

- **Acute hemorrhoidal attacks** : 3 tablets twice daily for the first 4 days, then 2 tablets twice daily for three 7 days and if required 1 tablet twice daily as maintenance dosage.
- **Chronic hemorrhoids** : 1 tablet twice daily.
- **Chronic venous insufficiency** : 1 tablet twice daily initially for seven days.

Duration may be increased depending on severity.

**CONTRAINDICATION AND PRECAUTION**

Proper data on contraindication is not available. If the hemorrhoidal symptoms do not disappear within 15 days, patient should ask doctor for advice.

**SIDE EFFECT**

Some cases of routine gastric disorders and neurovegetative disorders (feeling of discomfort) have been reported. In this cases discontinuation of treatment is not required.

**DRUG INTERACTION**

Proper data is not available.

**USE IN PREGNANCY AND LACTATION**

Experimental studies in animal have not demonstrated any teratogenic effects and no harmful effect have been reported in women to date. Breast feeding is not recommended during treatment.

**STORAGE CONDITION**

Store at a cool & dry place, protect from light & moisture.

**HOW SUPPLIED**

Each box containing 3X10's tablets in blister pack.



Manufactured by  
**Apex Pharma Ltd.**  
Shafipur, Gazipur